Skip to main content
Pfizer10-Q: Bookings decline

Pfizer reports continued revenue decline from COVID-19 products Comirnaty and Paxlovid.

What happened

The company's overall revenue growth is being dampened by a significant decline in its COVID-19 franchise. This creates pressure to find new revenue streams and accelerate growth in other product areas to compensate for the fall-off in this major portfolio.

Source

SEC EDGARMay 5, 2026

Quarterly report (Form 10-Q)

Pfizer 10-Q

Filing excerpt

The operational increase was primarily driven by an increase in revenues for Padcev, Eliquis, Oncology biosimilars, Nurtec ODT/Vydura and several other products across categories, partially offset primarily by a decline in COVID-19 product revenues.

sec.gov/Archives/edgar/data/78003/000007800326000054/pfe-20260329.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Bookings decline

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
03/29
Filed
May 5, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
7% (Operational revenue increase excluding Comirnaty and Paxlovid)

Details

CIK
78003
Accession number
0000078003-26-000054
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Sales effectiveness tools
Signal category
Revenue

Extraction

Confidence
High
Relevance
80%
Sentiment
Negative
Detected
May 12, 2026
signal_type
sec-10q
signal_subtype
bookingsDecline

Use this data

Get every 10-Q signal for Pfizer and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Pfizer this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/98cd8c08-b180-48d3-9d76-035bf6f36a32 returns this record as JSON. POST /v1/companies/enrich returns every signal for pfizer.com.

{
  "signal_id": "98cd8c08-b180-48d3-9d76-035bf6f36a32",
  "signal_type": "sec-10q",
  "signal_subtype": "bookingsDecline",
  "detected_at": "2026-05-12T09:24:57.864+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "detail": "The company's overall revenue growth is being dampened by a significant decline in its COVID-19 franchise. This creates pressure to find new revenue streams and accelerate growth in other product areas to compensate for the fall-off in this major portfolio.",
    "metrics": {
      "pct": 0.07,
      "timeframe": "current_quarter",
      "pct_context": "Operational revenue increase excluding Comirnaty and Paxlovid"
    },
    "summary": "Pfizer reports continued revenue decline from COVID-19 products Comirnaty and Paxlovid.",
    "excerpts": "The operational increase was primarily driven by an increase in revenues for Padcev, Eliquis, Oncology biosimilars, Nurtec ODT/Vydura and several other products across categories, partially offset primarily by a decline in COVID-19 product revenues.",
    "relevance": 0.8,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/pfe-20260329.htm",
    "filing_date": "2026-05-05",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "03/29",
    "sales_relevance": "Sales effectiveness tools",
    "signal_category": "revenue"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.